SEC Form 4 · accession 0001209191-17-048081
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Krishna Yeshwant
Director
Period of report
Aug 4, 2017
Accepted (ET)
Aug 8, 2017 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 4, 2017 | S | 18,072 | $36.85 | D | 5,786 | D | |
| Common Stock | Aug 4, 2017 | M | 13,385 | $24.21 | A | 19,171 | D | |
| Common Stock | Aug 4, 2017 | F | 8,585 | $37.75 | D | 10,586 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | $24.21 | Aug 4, 2017 | M | 13,385 | D | Jun 18, 2015 | Jun 18, 2024 | Common Stock | 13,385 | 0 | D |
Explanation of responses
- F1The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.70 to $36.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.